On September 17, 2026 Altis Labs, Inc. ("Altis"), the AI endpoint company accelerating clinical trials, reported findings from an independent post-hoc analysis evaluating its AI-powered imaging endpoint, IPRO, in the MARIPOSA Phase 3 trial.1 The findings, which were presented at the World Conference on Lung Cancer (WCLC) 2026 in Seoul, Republic of Korea, show that Altis’ IPRO Response Rate detected an early, notable treatment effect, while RECIST-based objective response rate (ORR) failed to anticipate the investigational treatment’s 12+ month median overall survival (OS) benefit.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IPRO Response Rate provides early efficacy signal in EGFR-mutated NSCLC
In a post-hoc analysis performed by the trial sponsor, IPRO demonstrated its value as an early endpoint in the trial, which compared treatments in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The IPRO AI model automatically analyzed approximately 10,000 radiology scans, generating prognostic outcome measures for each patient at baseline and on-treatment assessments. IPRO Response was defined as a ≥50% improvement in the IPRO-α score relative to baseline, and the treatment effect was estimated as the IPRO Response Rate ratio for the investigational treatment versus control arm treatment at landmark early imaging assessments.
Key findings include:
IPRO Response Rate favored the investigational treatment beginning at Week 16 (IPRO Response Rate Ratio, 1.33; 95% CI, 1.03-1.71) and throughout subsequent time points, while ORR failed to anticipate the significant OS benefit throughout.
When evaluating pooled, patient-level IPRO trajectories over time, IPRO deterioration was consistently associated with OS detriment, while IPRO improvement was consistently associated with OS benefit.
IPRO scores for the entire trial were generated automatically from routinely acquired CT imaging, providing an objective, reproducible measure of efficacy.
"This readout proves that AI can anticipate meaningful clinical benefit that traditional imaging endpoints like ORR may fail to detect," said Felix Baldauf-Lenschen, Founder and CEO of Altis Labs. "We’re focused on supporting our biopharma partners and ultimately patients by bringing this level of precision into clinical trials so that efficacy can be detected earlier."
The results were presented on September 13th, 2026, at WCLC, Abstract/Poster: P1.046: IPRO-a Response Rate as a Potential Early Endpoint for Overall Survival in MARIPOSA, a Phase 3 Trial in EGFR-Mutated NSCLC. Abstract can be viewed at: View Source
(Press release, Altis Labs, SEP 17, 2026, View Source [SID1234670935])